KD PHARMA UK LIMITED

• ⚠

  Confirmation statement overdue

  Due 2026-05-10.

• ⚠

  Material uncertainty over going concern

  We draw attention to note 3 to the financial statements that describes the events and conditions that indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern.

1. KD PHARMA UK LIMITED 2019-05-10 → present
2. EPAX PHARMA UK LTD 2011-05-27 → 2019-05-10
3. TRYGG PHARMA UK LTD 2011-04-26 → 2011-05-27

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw attention to note 3 to the financial statements that describes the events and conditions that indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern.”

Significant events

• “Subsequent to the year end, as part of a wider O3 Group restructuring of operations, the company ceased production of Omega-3 products and changed its principal activity to the contract manufacture of small molecules.”
• “At the beginning of April 2025, as part of a wider restructuring of the O3 Group's global operations following the acquisition in 2024 of the Marine Lipids business from DSM-Firmenich AG, the company communicated to its employees a plan to cease the Omega 3 by the end of July 2025.”
• “On 6 January 2025, a fixed and floating charge was registered against the assets of the company as part of a wider O3 Group arrangement.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.